Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 89Cr 77Cr 72Cr 66Cr 125.11Cr 8.49TCr 126.5Cr 846.7Cr 332.32Cr 4.25TCr 335.18Cr 327.79Cr 14TCr P/E 2026 *
15.1x
P/E 2027 * 11.5x
Enterprise Value 121.77Cr 105.47Cr 98Cr 90Cr 170.71Cr 12TCr 172.61Cr 1.16TCr 453.45Cr 5.79TCr 457.36Cr 447.28Cr 19TCr EV / Sales 2026 *
1.63x
EV / Sales 2027 * 1.4x
Free-Float
50.29%
Yield 2026 *
-
Yield 2027 * -
1 day+1.71%
1 week-1.65%
Current month+1.50%
1 month+3.05%
3 months-13.47%
6 months-29.30%
Current year-24.42%
1 week 19.66
Extreme 19.665
20.46
1 month 18.41
Extreme 18.41
20.7
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
09/07/26 Free

Director

24,532 0.0556%
04/03/26 Tax

Chief Financial Officer

1,744 0.0038%
17/12/25 Fiscal year

Executive/Senior Manager

29,361 0.0639%
Change 5-day change 1-year change 3-year change Capi.($)
+1.71%-1.65%-5.60%-67.78% 89Cr
+4.86%-3.32%+52.73%+160.26% 1,04300Cr
+1.04%-2.99%+50.87%+52.38% 62TCr
+0.98%-6.49%+24.00%+66.66% 44TCr
+0.30%+3.62%+47.30%+38.27% 36TCr
+0.72%-1.04%+35.82%+39.63% 29TCr
-0.74%-5.88%+8.30%+9.98% 25TCr
+4.57%+5.21%+35.91%+67.64% 22TCr
+0.77%-10.00%+2.87%-45.43% 20TCr
-2.58%-0.73%+17.16%+67.46% 16TCr
Average +0.83%-3.59%+26.94%+38.91% 35.9TCr
Weighted average by Cap. +0.79%-3.79%+38.43%+76.15%

Financials

2026 *2027 *
Net sales 75Cr 65Cr 60Cr 55Cr 104.46Cr 7.09TCr 105.63Cr 707Cr 277.49Cr 3.55TCr 279.88Cr 273.71Cr 12TCr 78Cr 67Cr 63Cr 58Cr 109.16Cr 7.4TCr 110.38Cr 738.78Cr 289.96Cr 3.7TCr 292.46Cr 286.01Cr 12TCr
Net income 6.4Cr 5.54Cr 5.17Cr 4.75Cr 8.97Cr 608.56Cr 9.07Cr 61Cr 24Cr 304.49Cr 24Cr 24Cr 1.01TCr 8.4Cr 7.28Cr 6.78Cr 6.24Cr 12Cr 798.73Cr 12Cr 80Cr 31Cr 399.64Cr 32Cr 31Cr 1.32TCr
Net Debt 33Cr 28Cr 26Cr 24Cr 46Cr 3.09TCr 46Cr 308.62Cr 121.13Cr 1.55TCr 122.18Cr 119.48Cr 5.13TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.9TCr 28Cr 189.9Cr 75Cr 952.31Cr 75Cr 74Cr 3.15TCr
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
05/26/05 $20.24 +1.71% 3,51,618
04/26/04 $19.90 -1.58% 4,81,648
03/26/03 $20.22 +1.40% 4,13,179
31/26/31 $19.94 -2.16% 3,67,629
30/26/30 $20.38 -0.97% 3,55,683
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.24USD
Average target price
22.00USD
Spread / Average Target
+8.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock